GlobeNewswire Inc.··NaTempest's Dual-Targeting CAR-T Shows Promise as Clinical Data Update Looms
Tempest Therapeutics will present updated TPST-2003 CAR-T trial data at ISCT 2026, building on earlier 100% complete response rates in multiple myeloma patients.
TPSTclinical trialmultiple myeloma